WILLIAMS AND JENSEN, PLLC for PFIZER
What was lobbied
5 issue areas, each in the filer's own words, with who lobbied on it and where.
Budget/Appropriations BUD
Labor - HHS Appropriations FY 2020; Policies impacting Medicare Part D.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | COS, Rep Van Hilleary and Majority Whip |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shrd Employee, Ofc of the Speaker & Ofc of VA 7; Sr Policy Adv, Majority Leader, Rep Cantor; Sr. Policy Adv, Rep Whip, Rep Cantor; Sr. Policy Adv, Majority Whip, Rep Blunt; Prof Staff House Committee on E&C; Sr. LA to Rep Chris Cox |
Taxation/Internal Revenue Code TAX
Tax issues affecting the pharmaceutical industry including international tax. Implementation of the Tax Cuts and Jobs Act (P.L. 115-97).
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
Trade (domestic/foreign) TRD
IP protections related to trade agreements; trade policies impacting pharmaceutical development.
| Lobbyist | Covered position, as disclosed |
|---|---|
| CHRISTOPHER W HATCHER | — |
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | Shared employee, Ofc of the Speaker & Ofc of VA 07; Sr Policy Adv, Maj Leader, Rep. Cantor; Sr Policy Adv, Republican Whip, Rep. Cantor; Sr Policy Adv, Majority Whip, Rep. Blunt; Prof Staff House Committee on E & C; Sr LA to Rep. Cox |
| KARINA LYNCH | — |
Medicare/Medicaid MMM
Medicare payment issues including the Independent Payment Advisory Board (IPAB) and Medicaid issues. Medicare Part D. 101 drug pricing. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| GEORGE OLSEN | — |
Health Issues HCR
General education about policies impacting pharmaceutical development, approval and reimbursement; Drug safety and drug counterfeiting; Medicare Part D; Federal preemption for prescription drugs; drug importation; and drug shortages. S. 2543, Prescription Drug Pricing Reduction Act (PDPRA) of 2019 and H.R. 3, Lower Drug Costs Now Act of 2019.
| Lobbyist | Covered position, as disclosed |
|---|---|
| SUSAN HIRSCHMANN | — |
| MATTHEW B HOEKSTRA | — |
| CHERYL LYNN JAEGER | — |
| KARINA LYNCH | — |
| MELINDA M MAXFIELD | — |
| GEORGE OLSEN | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.